NA Drug modeling software Market - Industry Trends and Forecast to 2030

List of Tables

The drug modeling software market is expected to reach USD 16,808.81 million by 2030 from USD 8,504.35 million in 2022, growing at a CAGR of 9.2% during the forecast period of 2023 to 2033.

Market Segmentation:

North America Drug Modeling Software Market, By Component (Software, and Services), Operating System (Windows, Linux, Mac OS, and Others), Deployment Mode (Cloud Based, Hybrid Based, and On Premises), Enterprise Size(Large Enterprise Size, Small and Medium Enterprise Size), Application (Graphical Molecular Modeling, Gene Sequence Analysis, Protein Modeling, Modeling Crystal Structures, Cheminformatics, High Throughput Virtual Screening, Gas and Solution Phase Reaction, Medical Imaging, and Others), Purchase Model (Subscription Based, and One- Time License), End User( Pharmaceutical and Biotechnology Companies, Contract Research Organization, Research Institutes, Regulatory Authorities, and Others), Country ( U.S., Canada, Mexico)- Industry Trends and Forecast to 2030.

Overview of the Drug Modeling Software Market Dynamics :

Driver
Rising drug discovery and development activities
Restrain
Lack of quality data base
Opportunity
Cloud computing and big data analytics in drug modelling

Market Players:

The key market players operating in the drug modeling software market are listed below:

Dotmatics
BC Platforms
InSilicoTrials Technologies.
VeriSIM Life., Atomwise Inc.
Certara, USA.
GENECODE
Cresset., and Nanome Inc.
SIMULATIONS PLUS.
Dassault Systemes
Scripps Research
XtalPi Inc.
Xybion
ArgusLab
Schrodinger, Inc.

1 INTRODUCTION 57

1.1 OBJECTIVES OF THE STUDY 57
1.2 MARKET DEFINITION 57
1.3 OVERVIEW OF THE NORTH AMERICA DRUG MODELING SOFTWARE MARKET 57
1.4 CURRENCY AND PRICING 59
1.5 LIMITATIONS 59
1.6 MARKETS COVERED 59

2 MARKET SEGMENTATION 62

2.1 MARKETS COVERED 62
2.2 GEOGRAPHICAL SCOPE 63
2.3 YEARS CONSIDERED FOR THE STUDY 64
2.4 DBMR TRIPOD DATA VALIDATION MODEL 65
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 68
2.6 MULTIVARIATE MODELING 69
2.7 COMPONENT LIFELINE CURVE 69
2.8 DBMR MARKET POSITION GRID 70
2.9 VENDOR SHARE ANALYSIS 71
2.10 MARKET APPLICATION COVERAGE GRID 72
2.11 SECONDARY SOURCES 73
2.12 ASSUMPTIONS 73

3 EXECUTIVE SUMMARY 74

3.1 PORTER'S FIVE FORCES MODEL 78
3.2 VALUE CHAIN ANALYSIS 79
3.3 REGULATORY STANDARDS 80
3.4 TECHNOLOGICAL TRENDS 81
3.5 BENEFITS OF DRUG MODELING SOFTWARE 82

4 MARKET OVERVIEW 83

4.1 DRIVERS 85
- 4.1.1 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 85
- 4.1.2 RISING DEMAND FOR NOVEL THERAPIES 87
- 4.1.3 PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING 88
4.2 RESTRAINTS 89
- 4.2.1 LACK OF QUALITY DATA BASE 89
- 4.2.2 HIGH COST OF MANUFACTURING OF DRUG MODELLING SOFTWARE 89
4.3 OPPORTUNITIES 90
- 4.3.1 CLOUD COMPUTING AND BIG DATA ANALYTICS IN DRUG MODELLING 90
- 4.3.2 INCREASING ADOPTION OF MODELLING TOOLS IN DRUG DISCOVERY 91
4.4 CHALLENGES 91
- 4.4.1 LACK OF PROCEDURE FOR MULTI-DRUG EFFECT ASSESMENT 91
- 4.4.2 CHALLENGES WITH MODEL INTERPRETATION 92

5 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS 93

5.1 OVERVIEW 94
- 5.1.1 SOFTWARE 97
  - 5.1.1.1 INTEGRATED 98
  - 5.1.1.2 STANDALONE 98
  - 5.1.1.3 LIGAND BASED 98
  - 5.1.1.4 STRUCTURE BASED 98
5.2 SERVICES 98
- 5.2.1 PROFESSIONAL SERVICES 99
  - 5.2.1.1 CONSULTING AND TRAINING 100
  - 5.2.1.2 INTEGRATION AND IMPLEMENTATION 100
  - 5.2.1.3 SUPPORT AND MAINTENANCE 100
- 5.2.2 MANAGED SERVICES 100

6 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM 101

6.1 OVERVIEW 102
6.2 WINDOWS 105
6.3 LINUX 105
6.4 MAC OS 106
6.5 OTHERS 107

7 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE 108

7.1 OVERVIEW 109
7.2 CLOUD BASED 112
7.3 HYBRID-BASED 112
7.4 ON-PREMISES 113

8 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE 114

8.1 OVERVIEW 115
8.2 LARGE ENTERPRISE SIZE 118
8.3 SMALL & MEDIUM ENTERPRISE SIZE 118

9 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION 120

9.1 OVERVIEW 121
9.2 GRAPHICAL MOLECULAR MODELING 124
9.3 GENE SEQUENCE ANALYSIS 124
9.4 PROTEIN MODELING 125
9.5 MODELING CRYSTAL STRUCTURES 126
9.6 CHEMINFORMATICS 127
9.7 HIGH THROUGHPUT VIRTUAL SCREENING 128
9.8 GAS & SOLUTION PHASE REACTION 128
9.9 MEDICAL IMAGING 129
9.10 OTHERS 130

10 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL 131

10.1 OVERVIEW 132
10.2 SUBSCRIPTION BASED 135
- 10.2.1 ANNUALLY SUBSCRIPTION 136
- 10.2.2 MONTHLY SUBSCRIPTION 136
10.3 ONE-TIME LICENSE 136
- 10.3.1 GROUP LICENSE 137
- 10.3.2 DESKTOP LICENSE 137
- 10.3.3 OTHERS 137

11 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY END USER 138

11.1 OVERVIEW 139
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 142
- 11.2.1 LARGE ENTERPRISE SIZE 143
- 11.2.2 SMALL & MEDIUM ENTERPRISE SIZE 143
11.3 CONTRACT RESEARCH ORGANIZATIONS 143
- 11.3.1 LARGE ENTERPRISE SIZE 144
- 11.3.2 SMALL & MEDIUM ENTERPRISE SIZE 144
11.4 RESEARCH INSTITUTES 144
- 11.4.1 LARGE ENTERPRISE SIZE 145
- 11.4.2 SMALL & MEDIUM ENTERPRISE SIZE 145
11.5 REGULATORY AUTHORITIES 145
- 11.5.1 LARGE ENTERPRISE SIZE 146
- 11.5.2 SMALL & MEDIUM ENTERPRISE SIZE 147
11.6 OTHERS 147
- 11.6.1 LARGE ENTERPRISE SIZE 148
- 11.6.2 SMALL & MEDIUM ENTERPRISE SIZE 148

12 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY REGION 149

12.1 NORTH AMERICA 150
- 12.1.1 U.S. 160
- 12.1.2 CANADA 165
- 12.1.3 MEXICO 170

13 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: COMPANY LANDSCAPE 175

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 175

14 SWOT ANALYSIS 176

15 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, COMPANY PROFILE 177

15.1 DASSAULT SYSTEMES 177
- 15.1.1 COMPANY SNAPSHOT 177
- 15.1.2 REVENUE ANALYSIS 177
- 15.1.3 COMPANY SHARE ANALYSIS 178
- 15.1.4 PRODUCT PORTFOLIO 178
- 15.1.5 RECENT DEVELOPMENT 178
15.2 AMAZON WEB SERVICES, INC. OR ITS AFFILIATES.(A SUBSIDIARY OF AMAZON) 179
- 15.2.1 COMPANY SNAPSHOT 179
- 15.2.2 REVENUE ANALYSIS 179
- 15.2.3 COMPANY SHARE ANALYSIS 180
- 15.2.4 PRODUCT PORTFOLIO 180
- 15.2.5 RECENT DEVELOPMENTS 180
15.3 CERTARA, USA. 181
- 15.3.1 COMPANY SNAPSHOT 181
- 15.3.2 REVENUE ANALYSIS 181
- 15.3.3 COMPANY SHARE ANALYSIS 182
- 15.3.4 PRODUCT PORTFOLIO 182
- 15.3.5 RECENT DEVELOPMENTS 182
15.4 SCHRODINGER, INC. 183
- 15.4.1 COMPANY SNAPSHOT 183
- 15.4.2 REVENUE ANALYSIS 183
- 15.4.3 COMPANY SHARE ANALYSIS 184
- 15.4.4 PRODUCT PORTFOLIO 184
- 15.4.5 RECENT DEVELOPMENT 184
15.5 CRESSET. 185
- 15.5.1 COMPANY SNAPSHOT 185
- 15.5.2 COMPANY SHARE ANALYSIS 185
- 15.5.3 PRODUCT PORTFOLIO 186
- 15.5.4 RECENT DEVELOPMENTS 186
15.6 ACELLERA LTD 187
- 15.6.1 COMPANY SNAPSHOT 187
- 15.6.2 PRODUCT PORTFOLIO 187
- 15.6.3 RECENT DEVELOPMENTS 187
15.7 ARGUSLAB 188
- 15.7.1 COMPANY SNAPSHOT 188
- 15.7.2 PRODUCT PORTFOLIO 188
- 15.7.3 RECENT DEVELOPMENT 188
15.8 ATOMWISE INC. 189
- 15.8.1 COMPANY SNAPSHOT 189
- 15.8.2 PRODUCT PORTFOLIO 189
- 15.8.3 RECENT DEVELOPMENT 189
15.9 BC PLATFORMS 190
- 15.9.1 COMPANY SNAPSHOT 190
- 15.9.2 PRODUCT PORTFOLIO 190
- 15.9.3 RECENT DEVELOPMENTS 191
15.10 BIOSOLVEIT GMBH 192
- 15.10.1 COMPANY SNAPSHOT 192
- 15.10.2 PRODUCT PORTFOLIO 192
- 15.10.3 RECENT DEVELOPMENT 192
15.11 DOTMATICS 193
- 15.11.1 COMPANY SNAPSHOT 193
- 15.11.2 PRODUCT PORTFOLIO 193
- 15.11.3 RECENT DEVELOPMENTS 194
15.12 GENECODE 195
- 15.12.1 COMPANY SNAPSHOT 195
- 15.12.2 PRODUCT PORTFOLIO 195
- 15.12.3 RECENT DEVELOPMENT 195
15.13 INSILICOTRIALS TECHNOLOGIES. 196
- 15.13.1 COMPANY SNAPSHOT 196
- 15.13.2 PRODUCT PORTFOLIO 196
- 15.13.3 RECENT DEVELOPMENTS 197
15.14 NANOME INC. 198
- 15.14.1 COMPANY SNAPSHOT 198
- 15.14.2 PRODUCT PORTFOLIO 198
- 15.14.3 RECENT DEVELOPMENT 198
15.15 OPTIBRIUM, LTD. 199
- 15.15.1 COMPANY SNAPSHOT 199
- 15.15.2 PRODUCT PORTFOLIO 199
- 15.15.3 RECENT DEVELOPMENT 199
15.16 PHARMACELERA 200
- 15.16.1 COMPANY SNAPSHOT 200
- 15.16.2 PRODUCT PORTFOLIO 200
- 15.16.3 RECENT DEVELOPMENT 200
15.17 SIMULATIONS PLUS. 201
- 15.17.1 COMPANY SNAPSHOT 201
- 15.17.2 REVENUE ANALYSIS 202
- 15.17.3 COMPANY SHARE ANALYSIS 203
- 15.17.4 PRODUCT PORTFOLIO 203
- 15.17.5 RECENT DEVELOPMENT 204
15.18 THE SCRIPPS RESEARCH INSTITUTE 205
- 15.18.1 COMPANY SNAPSHOT 205
- 15.18.2 PRODUCT PORTFOLIO 205
- 15.18.3 RECENT DEVELOPMENT 205
15.19 VERISIM LIFE. 206
- 15.19.1 COMPANY SNAPSHOT 206
- 15.19.2 PRODUCT PORTFOLIO 206
- 15.19.3 RECENT DEVELOPMENTS 206
15.20 XTALPI INC. 207
- 15.20.1 COMPANY SNAPSHOT 207
- 15.20.2 PRODUCT PORTFOLIO 207
- 15.20.3 RECENT DEVELOPMENT 207
15.21 XYBION DIGITAL INC. 208
- 15.21.1 COMPANY SNAPSHOT 208
- 15.21.2 REVENUE ANALYSIS 208
- 15.21.3 PRODUCT PORTFOLIO 209
- 15.21.4 RECENT DEVELOPMENT 209

16 QUESTIONNAIRE 210

17 RELATED REPORTS 214

LIST OF TABLES

TABLE 1 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 58
TABLE 2 NORTH AMERICA SOFTAWARE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 59
TABLE 3 NORTH AMERICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 59
TABLE 4 NORTH AMERICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 60
TABLE 5 NORTH AMERICA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 61
TABLE 6 NORTH AMERICA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 61
TABLE 7 NORTH AMERICA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 62
TABLE 8 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 66
TABLE 9 NORTH AMERICA WINDOWS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 67
TABLE 10 NORTH AMERICA LINUX IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 11 NORTH AMERICA MAC OS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 68
TABLE 12 NORTH AMERICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 69
TABLE 13 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 73
TABLE 14 NORTH AMERICA CLOUD BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 74
TABLE 15 NORTH AMERICA HYBRID-BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 16 NORTH AMERICA ON-PREMISES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 75
TABLE 17 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 79
TABLE 18 NORTH AMERICA LARGE ENTERPRISE SIZE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 80
TABLE 19 NORTH AMERICA SMALL & MEDIUM ENTERPRISE SIZE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 81
TABLE 20 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 85
TABLE 21 NORTH AMERICA GRAPHICAL MOLECULAR MODELING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 86
TABLE 22 NORTH AMERICA GENE SEQUENCE ANALYSIS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 87
TABLE 23 NORTH AMERICA PROTEIN MODELING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 88
TABLE 24 NORTH AMERICA MODELING CRYSTAL STRUCTURES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 25 NORTH AMERICA CHEMINFORMATICS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 89
TABLE 26 NORTH AMERICA HIGH THROUGHPUT VIRTUAL SCREENING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 90
TABLE 27 NORTH AMERICA GAS & SOLUTION PHASE REACTION IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 91
TABLE 28 NORTH AMERICA MEDICAL IMAGING IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 29 NORTH AMERICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 92
TABLE 30 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 96
TABLE 31 NORTH AMERICA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 97
TABLE 32 NORTH AMERICA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 97
TABLE 33 NORTH AMERICA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 98
TABLE 34 NORTH AMERICA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 99
TABLE 35 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 103
TABLE 36 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 104
TABLE 37 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 104
TABLE 38 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 105
TABLE 39 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 106
TABLE 40 NORTH AMERICA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 107
TABLE 41 NORTH AMERICA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 107
TABLE 42 NORTH AMERICA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 108
TABLE 43 NORTH AMERICA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 108
TABLE 44 NORTH AMERICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY REGION, 2021-2030 (USD MILLION) 109
TABLE 45 NORTH AMERICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 109
TABLE 46 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY COUNTRY, 2021-2030 (USD MILLION) 117
TABLE 47 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 117
TABLE 48 NORTH AMERICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 117
TABLE 49 NORTH AMERICA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 117
TABLE 50 NORTH AMERICA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
TABLE 51 NORTH AMERICA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 118
TABLE 52 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 118
TABLE 53 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 118
TABLE 54 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 119
TABLE 55 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 119
TABLE 56 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 119
TABLE 57 NORTH AMERICA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 120
TABLE 58 NORTH AMERICA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 120
TABLE 59 NORTH AMERICA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 120
TABLE 60 NORTH AMERICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 120
TABLE 61 NORTH AMERICA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 121
TABLE 62 NORTH AMERICA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 121
TABLE 63 NORTH AMERICA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 121
TABLE 64 NORTH AMERICA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 121
TABLE 65 U.S. DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 122
TABLE 66 U.S. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 122
TABLE 67 U.S. SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
TABLE 68 U.S. SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 122
TABLE 69 U.S. PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 123
TABLE 70 U.S. DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 123
TABLE 71 U.S. DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 123
TABLE 72 U.S. DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 123
TABLE 73 U.S. DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 124
TABLE 74 U.S. DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 124
TABLE 75 U.S. SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 124
TABLE 76 U.S. ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 125
TABLE 77 U.S. DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 125
TABLE 78 U.S. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 125
TABLE 79 U.S. CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 125
TABLE 80 U.S. RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 126
TABLE 81 U.S. REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 126
TABLE 82 U.S. OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 126
TABLE 83 CANADA DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 127
TABLE 84 CANADA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 127
TABLE 85 CANADA SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
TABLE 86 CANADA SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 127
TABLE 87 CANADA PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 128
TABLE 88 CANADA DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 128
TABLE 89 CANADA DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 128
TABLE 90 CANADA DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 128
TABLE 91 CANADA DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 129
TABLE 92 CANADA DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 129
TABLE 93 CANADA SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 129
TABLE 94 CANADA ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 130
TABLE 95 CANADA DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 130
TABLE 96 CANADA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 130
TABLE 97 CANADA CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 130
TABLE 98 CANADA RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 131
TABLE 99 CANADA REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 131
TABLE 100 CANADA OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 131
TABLE 101 MEXICO DRUG MODELING SOFTWARE MARKET, BY COMPONENTS, 2021-2030 (USD MILLION) 132
TABLE 102 MEXICO SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION) 132
TABLE 103 MEXICO SOFTWARE IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
TABLE 104 MEXICO SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 132
TABLE 105 MEXICO PROFESSIONAL SERVICES IN DRUG MODELING SOFTWARE MARKET, BY TYPE, 2021-2030 (USD MILLION) 133
TABLE 106 MEXICO DRUG MODELING SOFTWARE MARKET, BY OPERATING SYSTEM, 2021-2030 (USD MILLION) 133
TABLE 107 MEXICO DRUG MODELING SOFTWARE MARKET, BY DEPLOYMENT MODE, 2021-2030 (USD MILLION) 133
TABLE 108 MEXICO DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 133
TABLE 109 MEXICO DRUG MODELING SOFTWARE MARKET, BY APPLICATION, 2021-2030 (USD MILLION) 134
TABLE 110 MEXICO DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 134
TABLE 111 MEXICO SUBSCRIPTION BASED IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 134
TABLE 112 MEXICO ONE-TIME LICENSE IN DRUG MODELING SOFTWARE MARKET, BY PURCHASING MODEL, 2021-2030 (USD MILLION) 135
TABLE 113 MEXICO DRUG MODELING SOFTWARE MARKET, BY END USER, 2021-2030 (USD MILLION) 135
TABLE 114 MEXICO PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 135
TABLE 115 MEXICO CONTRACT RESEARCH ORGANIZATIONS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 135
TABLE 116 MEXICO RESEARCH INSTITUTES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 136
TABLE 117 MEXICO REGULATORY AUTHORITIES IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 136
TABLE 118 MEXICO OTHERS IN DRUG MODELING SOFTWARE MARKET, BY ENTERPRISE SIZE, 2021-2030 (USD MILLION) 136

LIST OF FIGURES

FIGURE 1 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: SEGMENTATION 22
FIGURE 2 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: DATA TRIANGULATION 25
FIGURE 3 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: DROC ANALYSIS 26
FIGURE 4 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: NORTH AMERICA VS. REGIONAL MARKET ANALYSIS 27
FIGURE 5 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: COMPANY RESEARCH ANALYSIS 27
FIGURE 6 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: INTERVIEW DEMOGRAPHICS 28
FIGURE 7 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: MULTIVARIATE MODELING 29
FIGURE 8 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: DBMR MARKET POSITION GRID 30
FIGURE 9 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: VENDOR SHARE ANALYSIS 31
FIGURE 10 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: MARKET APPLICATION COVERAGE GRID 32
FIGURE 11 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: SEGMENTATION 36
FIGURE 12 RISING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES, RISING DEMAND FOR NOVEL THERAPIES, AND PRECISION MEDICINE AND INTERVENTION OF AI IN DRUG MODELLING ARE ARE EXPECTED TO DRIVE THE NORTH AMERICA DRUG MODELING SOFTWARE MARKET GROWTH IN THE FORECAST PERIOD FROM 2023 TO 2030 37
FIGURE 13 SOFTWARE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA DRUG MODELING SOFTWARE MARKET IN 2023 & 2030 37
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA DRUG MODELING SOFTWARE MARKET 44
FIGURE 15 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, 2022 54
FIGURE 16 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, 2023-2030 (USD MILLION) 55
FIGURE 17 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, CAGR (2023-2030) 55
FIGURE 18 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS, LIFELINE CURVE 56
FIGURE 19 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, 2022 62
FIGURE 20 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, 2023-2030 (USD MILLION) 63
FIGURE 21 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, CAGR (2023-2030) 63
FIGURE 22 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY OPERATING SYSTEM, LIFELINE CURVE 64
FIGURE 23 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, 2022 69
FIGURE 24 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, 2023-2030 (USD MILLION) 70
FIGURE 25 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, CAGR (2023-2030) 70
FIGURE 26 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY DEPLOYMENT MODE, LIFELINE CURVE 71
FIGURE 27 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, 2022 75
FIGURE 28 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, 2023-2030 (USD MILLION) 76
FIGURE 29 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, CAGR (2023-2030) 76
FIGURE 30 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY ENTERPRISE SIZE, LIFELINE CURVE 77
FIGURE 31 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY APPLICATION, 2022 81
FIGURE 32 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY APPLICATION, 2023-2030 (USD MILLION) 82
FIGURE 33 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY APPLICATION, CAGR (2023-2030) 82
FIGURE 34 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY APPLICATION, LIFELINE CURVE 83
FIGURE 35 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, 2022 92
FIGURE 36 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, 2023-2030 (USD MILLION) 93
FIGURE 37 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, CAGR (2023-2030) 93
FIGURE 38 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY PURCHASING MODEL, LIFELINE CURVE 94
FIGURE 39 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY END USER, 2022 99
FIGURE 40 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY END USER, 2023-2030 (USD MILLION) 100
FIGURE 41 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY END USER, CAGR (2023-2030) 100
FIGURE 42 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY END USER, LIFELINE CURVE 101
FIGURE 43 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: SNAPSHOT (2022) 111
FIGURE 44 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022) 113
FIGURE 45 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2023 & 2030) 113
FIGURE 46 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COUNTRY (2022 & 2030) 114
FIGURE 47 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: BY COMPONENTS (2023-2030) 114
FIGURE 48 NORTH AMERICA DRUG MODELING SOFTWARE MARKET: COMPANY SHARE 2022 (%) 135